Maria Helena P Rigatto - Infectious Diseases

Author Information

Maria Helena Rigatto is a distinguished researcher affiliated with the Infectious Diseases Service at Hospital São Lucas da PUCRS in Porto Alegre, Brazil. Her work primarily focuses on infectious diseases, including studies on antimicrobial resistance and the clinical management of infections. Her contributions have been pivotal in advancing understanding in these areas, particularly in the context of treatment strategies for resistant bacterial infections and the impact of such infections on patient outcomes.

Research Contributions

Maria Helena Rigatto has made significant contributions to the field of infectious diseases through her research on antimicrobial stewardship, the efficacy and toxicity of antibiotics like Amikacin and Polymyxin B, and the epidemiology of drug-resistant infections. Her research spans the development of artificial intelligence-based methods for COVID-19 diagnosis and the investigation of drug resistance mutations in high-prevalence settings. Rigatto's work has also explored the impact of resistant infections on sepsis mortality and the development of strategies to mitigate antibiotic toxicity.

Aliases

Maria Helena Rigatto has published under several aliases, including Maria H Rigatto, Maria Helena Rigatto, M H Rigatto, M Rigatto, and Maria Helena P Rigatto. These variations reflect her contributions across different publications and collaborations in her field.

Publication and Citation Metrics

Metric	Value
Total Papers	48
Total Citations	751
h-index	14

Publications:

1266. Melatonin for Renal Protection of Patients Treated with Polymyxin B: A Double Blind Randomized Clinical Trial

DOI: 10.1093/ofid/ofab466.1458

Year: 2021

Antimicrobial Stewardship Program associated to earlier prescription of in vitro susceptible therapy and lower 14-day mortality in patients with carbapenem-resistant Enterobacterales (CRE) bacteremia: a cohort study

DOI: 10.1016/j.jgar.2021.12.011

Year: 2021

Amikacin for the treatment of carbapenem-resistant Klebsiella pneumoniae infections: clinical efficacy and toxicity.

DOI: 10.1007/s42770-021-00551-x

Year: 2021

Interaction Between Professors, Medical Students and Patients in the COVID-19 Era: An Educational Experience Report

DOI: 10.21801/PPCRJ.2020.64.7

Year: 2020

A novel specific artificial intelligence-based method to identify COVID-19 cases using simple blood exams

DOI: 10.1101/2020.04.10.20061036

Year: 2020

A Cohort Study of the Impact of Carbapenem-Resistant Enterobacteriaceae Infections on Mortality of Patients Presenting with Sepsis

DOI: 10.1128/mSphere.00052-19

Year: 2019

Impact of extended-spectrum β-lactamases and carbapenem-resistant Gram-negative infections on sepsis mortality at the emergency department: a cohort study.

DOI: 10.1016/j.jhin.2018.05.009

Year: 2019

Epidemiology of Transmitted Drug Resistance Mutations in a HIV-1 subtype-C high prevalence setting and impact on 1-year virological failure.

DOI: 10.1016/j.jgar.2019.11.006

Year: 2019

Clinical Use of Polymyxin B.

DOI: 10.1007/978-3-030-16373-0_14

Year: 2019

Polymyxin Acute Kidney Injury: Dosing and Other Strategies to Reduce Toxicity

DOI: 10.3390/antibiotics8010024

Year: 2019

How is Protein Targeting Relevant to Infectious Diseases?

What Role Do Antimicrobial Resistance Play?

How Does Viral Interference Occur?

How Do Pathogens Invade Hosts?

How Can We Improve Global Health Infrastructure to Combat Infectious Diseases?

What is the Global Impact of Hepatitis B?

What is Real-Time PCR?

What is the Role of the Zika Virus in Microcephaly?

What are Antiparasitics?

What Are Some Examples of Inherited Immunity?

Partnered Content Networks

Relevant Topics